
Urinary tract infections (UTIs) are a growing problem
Worldwide, an estimated 150 million people are affected by Urinary Tract Infections (UTIs) each year. Approximately 80% of these are caused by Escherichia coli (E. coli), often including difficult-to-treat strains that are resistant to commonly used antibiotics. Nearly 40% of patients with UTIs experience a recurrence within months of the first episode.
Both the U.S. Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) have identified antibiotic-resistant E. coli as an urgent and serious public health threat requiring the development of new treatments.
Who may participate?

UTIs affect millions of patients each year regardless of sex. The ELIMINATE Trial is initially studying the safety and efficacy of LBP-EC01 in adult women. ​
When you participate in a study, you’re helping find new ways to treat UTIs. Your participation can make a difference.
Condition
Urinary tract infection (UTIs) caused by drug-resistant E. coli
Age
18 - 75 years old
Sex
Female
Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.